ImmunityBio (NASDAQ:IBRX) Stock Price Crosses Below 200-Day Moving Average on Disappointing Earnings

ImmunityBio, Inc. (NASDAQ:IBRX)’s stock price passed below its two hundred day moving average during trading on Monday after the company announced weaker than expected quarterly earnings. The stock has a two hundred day moving average of $7.96 and traded as low as $6.36. ImmunityBio shares last traded at $7.11, with a volume of 44,782,144 shares.

The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The business had revenue of $48.84 million during the quarter, compared to the consensus estimate of $59.23 million.

Key ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Third-quarter net product revenue rose 53% year over year to $48.7 million, while U.S. revenue for the first nine months increased 92% to $143.6 million. ImmunityBio Q3 2026 results and approvals
• Positive Sentiment: ANKTIVA plus BCG met the primary endpoint in a randomized trial for BCG-naïve, high-grade non-muscle-invasive bladder cancer, a potential clinical and commercial catalyst. QUILT-2.005 trial results
• Positive Sentiment: The company also reported an expanded FDA label and an additional global approval for ANKTIVA, broadening its regulatory reach. ImmunityBio Q3 2026 results and approvals
• Neutral Sentiment: Trading in IBRX call options was unusually active, with volume 86% above its typical level; this does not establish a clear direction for the stock.
• Negative Sentiment: ImmunityBio reported a quarterly loss of $0.09 per share, worse than the $0.07 consensus estimate. Revenue of about $48.8 million also missed analysts’ $59.2 million forecast, and product sales declined from the prior quarter despite year-over-year growth. Q3 loss and revenue miss
• Negative Sentiment: The company disclosed “substantial doubt” about its ability to continue without additional funding, raising concerns about potential financing or dilution. The earnings miss and funding risk appear to be overshadowing the growth and pipeline news. Earnings, valuation, and funding concerns

Analyst Upgrades and Downgrades

IBRX has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of ImmunityBio in a research note on Tuesday, October 6th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of ImmunityBio in a research note on Thursday, October 15th. Piper Sandler reiterated an “overweight” rating and issued a $16.00 price target on shares of ImmunityBio in a report on Wednesday, October 14th. Finally, Jefferies Financial Group increased their price objective on shares of ImmunityBio from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Insider Transactions at ImmunityBio

In related news, Director Barry Simon sold 25,000 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $10.75, for a total transaction of $268,750.00. Following the completion of the transaction, the director directly owned 2,777,788 shares in the company, valued at approximately $29,861,221. This trade represents a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 81,056 shares of ImmunityBio stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total value of $851,088.00. Following the completion of the sale, the director directly owned 100,309 shares in the company, valued at approximately $1,053,244.50. This represents a 44.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 66.10% of the company’s stock.

Institutional Trading of ImmunityBio

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its holdings in ImmunityBio by 29.4% during the second quarter. BlackRock Inc. now owns 34,083,262 shares of the company’s stock worth $298,399,000 after buying an additional 7,736,819 shares during the last quarter. State Street Corp raised its position in ImmunityBio by 20.8% during the second quarter. State Street Corp now owns 21,398,438 shares of the company’s stock worth $187,343,000 after acquiring an additional 3,690,335 shares in the last quarter. SEB Asset Management AB acquired a new stake in ImmunityBio in the first quarter valued at $18,770,000. Bank of America Corp DE acquired a new stake in ImmunityBio in the second quarter valued at $19,125,000. Finally, Royal Bank of Canada lifted its stake in ImmunityBio by 1,731.8% in the first quarter. Royal Bank of Canada now owns 1,486,049 shares of the company’s stock valued at $11,399,000 after acquiring an additional 1,404,922 shares during the last quarter. 8.58% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio Stock Performance

The business’s 50-day moving average price is $8.72 and its 200 day moving average price is $7.96. The company has a market cap of $7.54 billion, a P/E ratio of -7.33 and a beta of 0.17.

About ImmunityBio

ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body’s natural and adaptive immune responses.

The company’s lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.